Cannabis Extracts Producer PharmaCielo Narrows Loss, Cuts Expenses In Q3, CEO Projects Higher Profitability
Cannabis Extracts Producer PharmaCielo Narrows Loss, Cuts Expenses In Q3, CEO Projects Higher Profitability
PharmaCielo Ltd. (TSXV:PCLO) (OTCQX:PCLOF) the Canadian parent of Colombia's cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., announced its financial results on Wednesday for the third quarter ended Sept. 30, 2023.
哥伦比亚种植商兼干花和药用级大麻提取物生产商Pharmacielo Ltd.（多伦多证券交易所股票代码：PCLO）（OTCQX: PCLOF）周三公布了截至2023年9月30日的第三季度财务业绩。
The company narrowed its net loss and selling, general and administrative expenses significantly year-over-year as well as an adjusted EBITDA loss, the report showed.
报告显示，该公司的净亏损和销售、一般和管理费用同比大幅缩小，调整后的息税折旧摊销前利润亏损也大幅缩小。
"Our team has built a focused and lean organization over the past twelve months, and effectively re-positioned the product portfolio on higher margin products," Marc Lustig, chairman and CEO said. "With total SG&A expenses down over 40% from Q3 of last year, and no meaningful capital expenditures necessary to get to full commercial scale, we are even better placed to generate higher profitability and cash flows as our sales efforts pay off."
董事长兼首席执行官马克·卢斯蒂格说：“在过去的十二个月中，我们的团队建立了一个专注而精益的组织，并在利润率更高的产品上有效地重新定位了产品组合。”“销售和收购总支出比去年第三季度下降了40％以上，而且无需进行任何有意义的资本支出即可实现全面商业规模，随着销售工作的回报，我们更有能力创造更高的盈利能力和现金流。”
Q3 2023 Financial Results
2023 年第三季度财务业绩
- Total revenue amounted to CA$351,688 ($258,777), down from CA$475,323 in the prior year's period.
- Gross loss totaled CA$349,187, up from $305,850 gross loss in the same quarter of 2022.
- Total selling, general, and administrative expenses amounted to roughly CA$2 million, down from CA$3.4 million in the corresponding period of last year.
- Net loss for the period totaled CA$2.8 million, down from CA$5.2 million in the prior year's period.
- Adjusted EBITDA came in negative at CA$1.4 million, compared to a negative adjusted EBITDA of CA2.4 million in the third quarter of 2022.
- As of Sept. 30, 2023, total assets amounted to CA26.6 million and total liabilities were CA$23.8 million, compared to CA$25.1 million and CA$18.7 million, respectively on Dec. 31, 2022.
- 总收入为351,688加元（合258,777美元），低于去年同期的475,323加元。
- 总亏损总额为349,187加元，高于2022年同期的305,850美元。
- 销售、一般和管理费用总额约为200万加元，低于去年同期的340万加元。
- 该期间的净亏损总额为280万加元，低于去年同期的520万加元。
- 调整后的息税折旧摊销前利润为负140万加元，而2022年第三季度的调整后息税折旧摊销前利润为负240万加元。
- 截至2023年9月30日，总资产为2660万加元，总负债为2,380万加元，而截至2022年12月31日，分别为2510万加元和1,870万加元。
PCLOF Price Action
PCLOF 价格走势
PharmaCielo's shares traded 6.8453% lower at $0.1311 per share after the market close on Tuesday afternoon.
周二下午市场收盘后，Pharmacielo的股价下跌6.8453％，至每股0.1311美元。
Did you miss the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
你错过了第一波大麻投资浪潮吗？别再犯那个错误了。
专家认为，大麻股票已经下跌，现在有望实现前所未有的增长。
加入 Benzinga PotProfit我们的内部大麻股票专家迈克尔·伯杰的使命是发现即使在低迷的市场中也有望增长的最有前途的大麻股票。他不遗余力地为你带来最丰厚的潜在两位数机会！
就在今年，PotProfits投资组合的涨幅火爆，例如：
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
- 47.10% 使用 $GTBIF
- 使用 $TCNNF 获得 40.23%
- 21.50% 使用 $VFF
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.Don't miss out on the green rush!
但关键在此：迈克尔即将发布他的下一个潜在赢家，他正在努力尽快与你分享这些股票符号。千万不要错过绿色热潮！
Related News
相关新闻
- PharmaCielo Q2 2023 Results: Revenue Drops But CEO Is Optimistic About Future Growth
- PharmaCielo Q1 2023: Revenue Down 34.2% YoY, CEO Expects Robust Global Sales Of Cannabis Flower In 2023
- PharmaCielo FY 2022 Revenue Grows 173%, What About Adjusted EBITDA?
- PharmaciELO 2023 年第二季度业绩：收入下降但首席执行官对未来增长持乐观态度
- PharmaciELO 2023 年第一季度：收入同比下降34.2％，首席执行官预计 2023 年大麻花的全球销售将强劲
- PharmaciELO 2022 财年收入增长了 173%，调整后的息税折旧摊销前利润呢？
Photo: Courtesy of Elsa Olofsson on Unsplash
照片：由 Unsplash 上的 Elsa Olofsson 提供